This study aims to investigate the associations of hypomethylation and over expression of the TLR9 gene with systemic lupus erythematosus (SLE). METHODS: Fifteen SLE patients who were diagnosed and not treated, were selected as cases, and 32 healthy subjects were enrolled as controls. DNA and total RNA of peripheral blood mononuclear cells (PBMCs) were extracted. The methylation status of the promoter region CpG motifs of the TLR9 gene was quantitatively measured using bisulfite sequencing PCR (BSP), and the mRNA expression of the TLR9 gene was determined using real-time fluorescent quantitative PCR.
Introduction
In recent years, approximately 30 susceptibility genes were suggested playing a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Most of these genes were involved in three biological processes, the removal of immune complexes, Toll-like receptor (TLR) function and production of interferon-1 (type-I interferon, IFN-1), and immune signal transduction of lymphocytes. The DNA methylation status induced by environmental and other factors, in particular, abnormal low DNA methylation in immune disorder, may cause autoimmune response. These changes may contribute to the occurrence and development of SLE [1] .
Toll-like receptor 9 (TLR9) is a member of the TLR family. Through the identification of conserved pathogen-associated molecular patterns (PAMPs), TLR9 is involved in specific immune responses, bridging the gap between natural immunity and specific immunity [2] . TLR9 is specifically identifying CpG motifs, which has a core nucleotide sequence containing unmethylated cytosine-guanine dinucleotide, the combination activates the myeloid differentiation protein 88 (MyD88)-dependent signaling pathway, finally activates nuclear factor NF-κB. It leads to the expression of a series of pro-inflammatory cytokine genes and the activation of immune cells [2, 3] , and subsequently, the abnormal survival, differentiation and proliferation of B cells and the production of antibodies [4] . The process results in the abnormal activation of plasmacytoid dendritic cells (pDC) and release of a large amount of IFN-1. Hence, TLR9 plays an important role in autoimmune and inflammatory processes [5] . A recent study also revealed that the mRNA expression level of the TLR9 gene was closely related to SLE conditions [6] . To further dissect the role of TLR9 in SLE pathogenesis, in the present study, we UV light. PCR product was purified by TIANgel Midi Purification Kit. The purified PCR product was connected to a T vector using the pGEM ® -T Easy Vector System II (Promege, USA).
Based on blue-white selection, the white colonies that contained target sequence, were picked and performed PCR amplification using universal primers M13F and M13R (Dalian TaKaRa Biotech). The PCR amplification product was sent for sequencing. Analysis of sequencing was conducted by BiQ Analyzer software.
In this study, the 10 Cp G motifs in the proximal promoter region of the TLR9 gene was studied (-736, -683, -620, -546, -488, -481, -389, -105, -78 and -35). The test of normality (Shapiro-Wilk test) on the methylation rates and overall methylation rates of the 10 Cp G motifs in the promoter region of TLR9 gene in 15 SLE patients and 32 healthy controls were conducted using SPSS 17.0 software. The data that was not normally distributed (P<0.05) were analyzed using nonparametric rank sum test. Comparisons between groups were conducted using Kruskal-Wallis test. Inspection level was set as α = 0.05.
Detection of TLR9 gene mRNA expression by RT-PCR
Trizol method was used to extract mRNA from the PBMC samples, and mRNA quality was checked by micro UV/VIS spectrophotometer. When score of A260/A280 was in 1.6-2 and mRNA samples were preserved to -80°C. Synthesis of cDNA was conducted via reverse transcription reaction using a PrimeScript ® RT reagent kit with gDNA Eraser (TaKaRa Biotech). Shapiro-Wilk test was conducted on the methylation rates of the 10 CpG motifs in 15 cases 32 controls by SPSS 17.0 software. If results revealed that only part of the data was normally distributed, or all data was not normally distributed, these data were compared using nonparametric rank sum test by Kruskal-Wallis test.
The relative mRNA expression levels of TLR9 in the active stage group, the remission stage group, and control group were compared using Shapiro-Wilk test by SPSS17.0 software. Results showed that the experimental data were normally distributed (P>0.05). The relative mRNA expression levels of TLR9 as mean ± standard deviation were compared using independent samples t-test among three groups. The relative m RNA expression levels of TLR9 in cases and controls were compared using Shapiro-Wilk test by SPSS 17.0 software. And the relative m RNA expression levels of TLR9 in patients in the active stage group, the remission stage group, and control group were also compared using Shapiro-Wilk test on the SPSS17.0 software. Results revealed that the experimental data were normally distributed (P>0.05). Therefore, the relative mRNA expression levels of TLR9 as mean ± standard deviation were compared using independent sample t-test between case with control, and different stage groups.
Results

Methylation status of the promoter region of the TLR9 gene in SLE cases and controls
The 10 CpG motifs (-736, -683, -620, -546, -488, -481, -389, -105, -78 and -35) in the promoter region of the TLR9 gene was evaluated using bisulfite sequencing PCR . It turned out that only part of the data was normally distributed. Therefore, these data were compared using nonparametric rank sum test (the Kruskal-Wallis test). We did detect the differences of methylation and the overal methylation levels between cases and controls among the 10 CpG motifs (P>0.05, Table 2 , but they did not show statistically significant (P>0.05, Figure 1 ).
Analysis of TLR9 gene expression in cases and controls
The experimental results revealed that the reaction efficiency of PCR was 90-110%, and that the dissolution curve had a single peak value. Moreover, electrophoresis was conducted on part of the RT-PCR products. It was found that the amplification fragments of the TLR9 and HPRT gene were unique, and the sizes were in accordance with expectancy. This suggests that the design of the primers was reasonable, which can be recorded in an Excel 2010 sheet to calculate the relative expression levels."
Statistical analysis of TLR9 gene expression in cases and controls
The results showed that the mRNA expression level of TLR9 was significantly higher in case group (167.685 ± 63.895) than in control group (2.816 ± 1.723), (P=9.379×10 -8 ; Figure 2 ).
When the SLE patients were divided into two groups according to the SLEDAI: the remission stage group, 6 patients had a SLEDAI of <10 points; and the active stage group, 9
patients had a SLEDAI of ≥10 points, we observed a higher TLR9 expression in the active stage (207.370 ± 25.227) than in the remission stage (88.316 ± 32.334) (P=2.664×10 -6 ). Also, the mRNA expression level of TLR9 was significantly higher in the active stage than the control group (2.816 ± 1.723) (P=9.674×10 -10 ). Similarly, the TLR9 mRNA expression level in the remission stage was significantly higher than the control group (P=0.04, Figure 3 ).
The TLR9 mRNA expression levels in SLE patients had a significant and positive linear correlation with SLEDAI (r=0.924, P=9.018×10 -7 ; Figure 4 ).
However, there was no correlation between the total methylation rate of the 10 CpG motifs in the promoter region of the TLR9 gene with the mRNA expression level of TLR9 in SLE patients (r=0.097, P=0.730; Figure 5 ).
Discussion
A large number of studies had revealed that gender, drugs, ultraviolet, bacterial or viral infections, and even diet can lead to changes in DNA methylation status [1] . and subsequently induce or aggravate the condition of SLE. The overall methylation level of the genome in PBMCs from SLE patients significantly decreased [8] . It was confirmed that a number of genes could regulate this pathway [9] . The excessive production of IFN-1 can accelerate the maturation of dendritic cells and promote the expression of cytokines and chemokines before inflammation, bringing about multiple effects to the function of the immune system, including the activation of autoreactive B and T cells, auto-antibody production, and loss of auto-tolerance [10] . TLR9 is one of the important genes in the IFN-1 signaling pathway, and its abnormal activation may be associated to the pathogenesis of SLE through the induction of the production of a large amount of IF-1 [5] .
Whole-genome DNA methylation analysis of CD4 + T cells, CD19 + B cells, and CD14 + monocytes in patients with SLE, the severe hypomethylation status of multiple genes involved in the IFN-1 signaling pathway was detected. It revealed that the methylation levels of 1,013 Cp Gs in T cells, 166 Cp Gs in B cells and 97 Cp Gs in monocytes in SLE patients significantly changed (P<1×10 -8 ) [11] . At present, no study has reported the relationship between the methylation status of the TLR9 gene with disease activity of SLE. Our results suggested that the overall methylation rate of the 10 CpG motifs in the promoter region of the TLR9 gene had a decreasing tendency in untreated primary SLE patients, but the difference was not statistically significant compared with the healthy control group (P>0.05). This result revealed that no abnormal methylation status of the 10 Cp G motifs in the promoter region of TLR9 was observed. TLR9 mRNA expression levels in SLE patients were positively correlated with SLEDAI. It was reported that the mRNA and protein expression levels of TLR9 in PBMCs were significantly higher in the active stage than in the remission stage and in healthy controls, and the differences between the latter two were also statistically significant [12, 13] . In addition, the mRNA expression of TLR9 in PBMCs and B cells was higher in SLE patients than in controls, but the expression of TLR9 mRNA in pDC cells was not significantly different from that in controls [6, 14] . The expression of TLRs such as TLR7 and TLR9 in SLE patients was elevated, which had racial differences and may become a target of research for new therapeutic drugs [15] . It was reported that TLR3-and TLR9-positive cells in PBMCs, B cells (CD19 + ) and T cells (CD3 + , CD4 + , CD8 + ) were significantly higher in SLE patients compared with healthy controls, the TLR7-positive cells in B cells (CD19 + ) was significantly higher in SLE patients compared with healthy controls. But, no correlation between the disease activity index (DAI) with disease damage index (DDI) was found. In some clinical symptoms such as arthritis, laboratory indicators such as the decrease in lymphocytesand granulocyte, anemia and increase in erythrocyte sedimentation rate (ESR), as well as menopause in female patients, suggested that TLR3, TLR7 and TLR9 play certain roles in organ damage in SLE [16] . Based on RT-PCR method to determine the mRNA levels of TLR9 and interferon regulatory factor 5 (IRF5) in PBMCs in Chinese patients with SLE, revealed that TLR9 expression in SLE patients increased (P=0.011) [17] . It was revealed that the mRNA levels of SLEDAI, ds-DNA, ANA and TLR9 were significantly elevated in SLE patients in the active stage [18] . A retrospective study revealed that TLR9 expression was significantly higher in the hormone resistance group than in the hormone sensitivity group before treatment, but there was no difference after treatment. Our results revealed that the mRNA expression level of TLR9 was significantly higher in untreated primary SLE patients compared with controls. Furthermore, for SLE patients, those in the active stage showed a significantly higher expression of TLR9 than those in the remission stage, and both SLE stages showed a higher TLR9 expression than the healthy controls. 
